Navigation Links
Profiling of Cancer Genes May Lead to Earlier Detection Human Cancers

A research team at UT Southwestern Medical Center has for the first time identified several genes// whose expression is lost in four of the most common solid human cancers – lung, breast, prostate and colon cancer.

The expression of genes that inhibit cancer development, so-called tumor suppressor genes, is often lost in tumor cells. This can occur through a mutation in the gene’s DNA sequence or through deletion of the gene. Loss of tumor suppression function also can occur in a process called methylation, where a chemical called a methyl group is attached to a DNA region near the gene and prevents it from being activated, essentially “silencing” the gene.

“These results show the power of studying tumors on a genome-wide basis, looking at many genes at the same time,” said Dr. John Minna, the study’s senior author and director of the W.A. “Tex” and Deborah Moncrief Jr. Center for Cancer Genetics and the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research at UT Southwestern.

In an effort to identify new tumor-suppressor genes that might be important to lung and breast cancer development, the UT Southwestern team examined which genes are active in those kinds of tumors and compared them to gene expression profiles from normal lung epithelial cells. The researchers then examined the gene expression profiles of these various cell types before and after treatment with a drug that inhibits methylation.

The researchers identified approximately 130 genes that may be methylated and thus silenced in lung, breast, prostate and colon cancers. They analyzed 45 of these new genes in both normal and cancerous tissues from the same patients and found that many of the genes were methylated specifically in the tumor samples.

“We ended up with a large number of genes that are involved in the development of lung cancer that, despite years of work in the field, I had never connected to lung cancer before,” sai d Dr. Minna.

Patient samples from UT Southwestern’s new Harold C. Simmons Comprehensive Cancer Center tissue repository and previous results from study author Dr. David Euhus allowed the research team to quickly extend its findings to breast, prostate and colon cancer. A Hamon Center postdoctoral researcher and lead study author Dr. David Shames was instrumental in identifying the genes, Dr. Minna said.

“What would have normally taken us several years, David Shames was able to determine in less than a month,” Dr. Minna said. “The new genes Dr. Shames discovered are now forming the basis for a new early detection screen that could be mounted against the most common human cancers.”

The genes the researchers found to be methylated specifically in the tumor samples might control the conversion of normal cells into cancer cells, Dr. Minna said, but this possibility needs to be tested on a case-by-case basis.

Although it is known that gene expression patterns in tumors vary greatly from tissue to tissue, the researchers hope that the similarities of the methylation patterns found in this study might lead to a better approach to detect cancer early and help identify new promising therapeutic targets to treat some of the most prevalent cancers.

“The findings from our study suggest that it may be possible to develop a methylation profiling platform that could be used to screen patients for common solid tumors, while at the same time identify what type of tumor the patient may have,” Dr. Shames said.

The study also illustrates that some of the basic processes that underlie the development of breast and lung cancer are identical, even though the chemicals that initiate those processes – estrogen and tobacco carcinogens, for example – may be different, said Dr. Euhus, associate professor of surgical oncology.

“I was also struck that some of these processes could be detected in benign breast cel ls from high-risk women, more so than in lower-risk women,” said Dr. Euhus, co-director of the Mary L. Brown Breast Cancer Genetics and Risk Assessment Program. “Methylation is potentially a reversible change and there may be some interventions that would effectively reduce the risk of several types of cancer simultaneously.”
SRM
'"/>




Related medicine news :

1. Nutrient Profiling System Launched By Food Officials in UK
2. Proteomic Profiling Can Detect Preterm Birth Risk
3. Fibroids unlikely to Turn Cancerous
4. Virus Level could Predict Cervical Cancer Risk
5. Cancer Doctors Okays Controversial Prostate Therapy
6. Potential New Cancer Gene Identified
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Cancer drugs in development nearly doubled since 1995
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... September 22, 2017 , ... TopConsumerReviews.com ... by Native Remedies that helps promote pancreatic health and regulate blood sugar ... some prescription-based approaches can have negative side effects, and with the changes in ...
(Date:9/22/2017)... , ... September 22, 2017 , ... “Letters From Home”: ... people, even the lost, have value to God. “Letters From Home” is the creation ... a member of the President’s Cabinet of Jerry Savelle Ministries International, who has traveled ...
(Date:9/21/2017)... ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery ... is pleased to announce that Plastic Surgeon Kiranjeet Gill has been awarded as one ... is an annual award that was started in 2003 to salute young achievers in ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for Children® ... the election of Yie-Hsin Hung to the Board of Directors. , “The New ... Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, Jr., ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... focused on the development of oral drug delivery systems, ... with the U.S. Food and Drug Administration (FDA) regarding ... At the meeting, the FDA ... of ORMD-0801, would be a Biologics License Application (BLA).  ...
(Date:9/1/2017)... WHIPPANY, N.J. , Sept. 1, 2017  Bayer will ... at the European Society for Medical Oncology (ESMO) 2017 Congress, ... studies presented will include new preclinical and clinical data on ... from two earlier pipeline projects. ... of the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... RANDOLPH, N.J. , Aug. 29, 2017 ... inventory management, security, and regulatory compliance for veterinary practices ... today announced a new partnership that makes TITAN,s expertise ... legal compliance available to Cubex,s clients nationally. ... healthcare provider buying and handling controlled substances is at ...
Breaking Medicine Technology: